Sysmex Europe

Haematologic malignancies: Get more out of routine diagnostics

Join us and explore our innovative aid to diagnosis solutions in the field of haematologic malignancies!

For more than 50 years we at Sysmex have paired our high-quality haematology analysers with the knowledge of our customers and medical experts, resulting in solutions for profound blood cell characterisation: from cell count to cell morphology and functionality, to clinical flow cytometry and its dedicated antibodies.

We have moved beyond the traditional complete blood count (CBC) and arrived at aid to diagnosis solutions allowing an unmatched level of insight in patients haematopoiesis and blood cell physiology – supporting better and faster detection and treatment of haematologic malignancies.

You are welcome to explore how our clinical insights can support you in diagnostics and therapy decision making.


[1] Da Rin G et al. (2017): Performance evaluation of the automated nucleated red blood cell count of five commercial hematological analyzers. Int J Lab Hematol. Dec; 39(6): 663–70.

[2] Bruegel M et al. (2015): Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000. Clin Chem Lab Med. Jun; 53(7): 1057–71.

[3] ] Blomme S et al. (2021): The integration of Sysmex XN-9100’ WPC channel reflex testing in the detection of reactive versus malignant blood samples. Int J Lab Hematol. Apr; 43(2): 191–198.

[4] Schuff-Werner P et al. (2016): Performance of the XN-2000 WPC channel-flagging to differentiate reactive and neoplastic leukocytosis. Clin Chem Lab Med. Sep 1; 54(9): 1503–10.

[5] Hoenemann C et al. (2021): Reticulocyte and Erythrocyte Hemoglobin Parameters for Iron Deficiency and Anemia Diagnostics in Patient Blood Management. A Narrative Review. J Clin Med. Sep; 10(18): 4250.

[6] Muñoz M et al. (2017): International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. Feb; 72(2): 233–247.

[7] Almashjary MN et al. (2022): Reticulocyte Hemoglobin-Equivalent Potentially Detects, Diagnoses and Discriminates between Stages of Iron Deficiency with High Sensitivity and Specificity. J Clin Med. Sep 26; 11(19): 5675.

[8] Auerbach M et al. (2021): Using Reticulocyte Hemoglobin Equivalent as a Marker for Iron Deficiency and Responsiveness to Iron Therapy. Mayo Clin Proc. Jun; 96(6): 1510–1519.

Copyright © Sysmex Europe SE. All rights reserved.